3-(2-甲氧基吡啶-4-基)丙烯酸乙酯 | 153902-00-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 3-(2-甲氧基吡啶-4-基)丙烯酸乙酯
• 英文名称: Ethyl-3-(2-methoxypyridin-4-yl)acrylate
• 英文别名: ethyl 3-(2-methoxypyridin-4-yl)prop-2-enoate
• CAS: 153902-00-2
• 化学式: C₁₁H₁₃NO₃
• 分子量: 207.229
• InChiKey: BRIXKMUCOHJVNK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  48.4
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-(2-甲氧基吡啶-4-基)丙烯酸乙酯 在 palladium on activated charcoal 吡啶 、 盐酸 、 氨 、 氢气 、 sodium methylate 、 sodium hydride 作用下， 以 甲醇 、 乙二醇二甲醚 、 乙醇 为溶剂， 反应 134.0h， 生成 2-amino-5-(2-hydroxypyrid-4-ylmethyl)-4-pyrimidone hydrochloride monohydrate
  参考文献：
  名称：

  Isocytosine H2-receptor histamine antagonists. IV. The synthesis and biological activity of donetidine (SK&F 93574) and related compounds

  摘要：

  The synthesis and biological activity of some novel 2-amino-4-pyrimidone derivatives is described. Side-chains associated with H-2-antagonist activity am attached through the 2-amino group, whilst a range of 2-hydroxypyridine containing moieties are substituted at the 5-position of the pyrimidone ring. Good H-2-receptor histamine antagonist activity is observed with all the series and the majority of the compounds are selective for the H-2-receptor. High aqueous solubility and iv potency coupled with an extended duration of biological activity in animal models led to compound 16c, 2-[2-(5-dimethylaminomethyl-2-furanylmethyl-thio)ethylamino]-5-(2-hydroxypyrid-4-ylmethyl)-4-pyrimidone (donetidine, SK&F 93574) being selected for clinical investigation as a potential parenterally administered therapeutic agent.

  DOI：

  10.1016/0223-5234(93)90091-r
• 作为产物：
  描述：

  4-氰基-2-甲氧基吡啶 在 镍 哌啶 、 吡啶 、 盐酸 、 聚合甲醛 、 氢气 、 盐酸氨基脲 、 sodium acetate 作用下， 反应 0.5h， 生成 3-(2-甲氧基吡啶-4-基)丙烯酸乙酯
  参考文献：
  名称：

  Isocytosine H2-receptor histamine antagonists. IV. The synthesis and biological activity of donetidine (SK&F 93574) and related compounds

  摘要：

  The synthesis and biological activity of some novel 2-amino-4-pyrimidone derivatives is described. Side-chains associated with H-2-antagonist activity am attached through the 2-amino group, whilst a range of 2-hydroxypyridine containing moieties are substituted at the 5-position of the pyrimidone ring. Good H-2-receptor histamine antagonist activity is observed with all the series and the majority of the compounds are selective for the H-2-receptor. High aqueous solubility and iv potency coupled with an extended duration of biological activity in animal models led to compound 16c, 2-[2-(5-dimethylaminomethyl-2-furanylmethyl-thio)ethylamino]-5-(2-hydroxypyrid-4-ylmethyl)-4-pyrimidone (donetidine, SK&F 93574) being selected for clinical investigation as a potential parenterally administered therapeutic agent.

  DOI：

  10.1016/0223-5234(93)90091-r

文献信息

• RENIN INHIBITORS
  申请人：McKay Daniel J.

  公开号：US20120035214A1

  公开（公告）日：2012-02-09

  The present invention relates to biaryl piperidine-based renin inhibitor compounds, and their use in treating cardiovascular events and renal insufficiency.

  本发明涉及基于联苯哌啶的肾素抑制剂化合物及其在治疗心血管事件和肾功能不全中的应用。
• Isocytosine H2-receptor histamine antagonists. IV. The synthesis and biological activity of donetidine (SK&F 93574) and related compounds
  作者：TH Brown、RC Blakemore、GJ Durant、CR Ganellin、ME Parsons、AC Rasmussen、DA Rawlings

  DOI：10.1016/0223-5234(93)90091-r

  日期：1993.1

  The synthesis and biological activity of some novel 2-amino-4-pyrimidone derivatives is described. Side-chains associated with H-2-antagonist activity am attached through the 2-amino group, whilst a range of 2-hydroxypyridine containing moieties are substituted at the 5-position of the pyrimidone ring. Good H-2-receptor histamine antagonist activity is observed with all the series and the majority of the compounds are selective for the H-2-receptor. High aqueous solubility and iv potency coupled with an extended duration of biological activity in animal models led to compound 16c, 2-[2-(5-dimethylaminomethyl-2-furanylmethyl-thio)ethylamino]-5-(2-hydroxypyrid-4-ylmethyl)-4-pyrimidone (donetidine, SK&F 93574) being selected for clinical investigation as a potential parenterally administered therapeutic agent.